A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Healthy Subjects
Latest Information Update: 06 Nov 2021
At a glance
- Drugs LY 2928057 (Primary)
- Indications Anaemia
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 14 Aug 2014 New trial record